Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Chemo, RT, and Erlotinib in Poor-Risk Stage III NSCLC
NCT00553462Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Mar 2008
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib and paclitaxel in non-small cell lung cancer (NSCLC), sponsored by Cancer and Leukemia Group B. Primary endpoint: Overall Survival at 12 months. Started Mar 2008; status: completed.
02
Drugs
erlotinibpaclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00553462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00553462.